Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 2, 2014, Pages

  Sinha, Ian P ^a   Southern, Kevin W ^a   Dwan, Kerry ^a   Patel, Sanjay ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CFTR GENE; CYSTIC FIBROSIS; GENE; GENE MUTATION; GENE THERAPY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THERAPY EFFECT;

EID: 85011266960     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010966     Document Type: Article

References (16)

1. Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends in Pharmacological Sciences 2007;28(7):334-41.
2. Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening. Human Mutation 2002;19(6):575-606.
3. Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto, Canada. Cystic Fibrosis Mutation Database. http://www.genet.sickkids.on.ca/app (accessed 23 September 2013).
4. Colledge WH, Abella BS, Southern KW, RatcliffR, Jiang C, Cheng SH, et al. Generation and characterization of a delta F508 cystic fibrosis mouse model. Nature Genetics 1995;10(4):445-52.
5. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
6. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
7. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
8. Higgins JPT, Deeks JJ, Altman DG on behalf of the CSMG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
9. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
10. Riordan JR, Rommens JM, Kerem BS, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene - cloning and characterization of complementary. Science 1989;245(4922):1066-72.
11. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 2011;139(6):1480-90. [DOI: 10.1378/chest.10-2077]
12. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Annals of Human Genetics 2003;67(5):471-85.
13. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. Journal of Clinical Investigation 1997;100(10):2457-65.
14. Southern KW. Delta F508 in cystic fibrosis: Willing but not able. Archives of Disease in Childhood 1997;76(3):278-82.
15. Southern KW. Cystic fibrosis and formes frustes of CFTR-related disease. Respiration: International Review of Thoracic Diseases 2007;74(3):241-51.
16. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proceedings of the National Academy of Sciences of the United States of America 2011;108(46):18843-8. [DOI: 10.1073/pnas.1105787108]